EGFR amplification and EGFRvIII predict and participate in TAT-Cx43266–283 antitumor response in preclinical glioblastoma models

[Background]: Glioblastoma (GBM) commonly displays epidermal growth factor receptor (EGFR) alterations (mainly amplification and EGFRvIII) and TAT-Cx43266–283 is a Src-inhibitory peptide with antitumor properties in preclinical GBM models. Given the link between EGFR and Src, the aim of this study w...

Descripción completa

Detalles Bibliográficos
Autores: Álvarez-Vázquez, Andrea, San-Segundo, Laura, Cerveró-García, Pilar, Flores-Hernández, Ollauri‑Ibáñez, Claudia, Segura-Collar, Berta, Hubert, Christopher G., Morrison, Gillian, Pollard, Steven M., Lathia, Justin D., Sánchez-Gómez, Pilar, Tabernero, Arantxa
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2024
País:España
Institución:Consejo Superior de Investigaciones Científicas (CSIC)
Repositorio:DIGITAL.CSIC. Repositorio Institucional del CSIC
OAI Identifier:oai:digital.csic.es:10261/380871
Acceso en línea:http://hdl.handle.net/10261/380871
Access Level:acceso abierto
Palabra clave:Cell-penetrating peptides
EGFR
Glioblastoma
NSCs
Src
Descripción
Sumario:[Background]: Glioblastoma (GBM) commonly displays epidermal growth factor receptor (EGFR) alterations (mainly amplification and EGFRvIII) and TAT-Cx43266–283 is a Src-inhibitory peptide with antitumor properties in preclinical GBM models. Given the link between EGFR and Src, the aim of this study was to explore the role of EGFR in the antitumor effects of TAT-Cx43266–283.

Similares en LA Referencia